| Category: |
Antineoplastics, Hormone Therapy (Aromatase Inhibitor)
|
| PRODUCT INFORMATION : |
Generic Name: ANASTROZOLE
Composition: Each film-coated tablet contains Anastrozole 1 mg
Pharmacological Category: Non-steroidal Aromatase Inhibitor
Pregnancy Category: X
Lactation: Not recommended
Pack Size: 5 x 10’s
|
| INDICATIONS : |
- Hormone receptor-positive early breast cancer (postmenopausal women)
- Advanced or metastatic breast cancer in postmenopausal women
- Adjuvant treatment after surgery/radiation
- Prevention of breast cancer recurrence
|
| MECHANISM OF ACTION:: |
Anastrozole
↓
Inhibits Aromatase enzyme
↓
↓ Conversion of androgens → estrogen
↓
↓ Estrogen levels in circulation
↓
↓ Estrogen receptor activation
↓
↓ Tumor cell proliferation
↓
Tumor regression / Delayed progression
|
| PHARMACOKINETICS: |
Absorption: Rapid and well absorbed orally
Bioavailability: High
Onset of Action: Within days (clinical effect over weeks)
Metabolism: Hepatic
Excretion: Urine
|
| DOSAGE INFORMATION: |
Adults: 1 mg once daily
Note: Long-term therapy (usually 5 years) under oncologist supervision
|
| SIDE EFFECTS: |
- Hot flashes
- Arthralgia (joint pain)
- Osteoporosis / bone loss
- Nausea
- Fatigue
- Increased cholesterol levels
|
| PRECAUTIONS: |
Use with caution in patients with:
- Osteoporosis
- Cardiovascular disease
- Hepatic impairment
Monitoring:
- Bone mineral density
- Lipid profile
|
| CONTRAINDICATIONS: |
- Pregnancy (Category X)
- Premenopausal women (unless specifically indicated)
- Hypersensitivity to Anastrozole
|
